Free Trial
→ The Iran War Just Broke the Gold Market (From Behind the Markets) (Ad)tc pixel
NASDAQ:CADL

Candel Therapeutics Q2 2024 Earnings Report

Candel Therapeutics logo
$7.67 +0.14 (+1.86%)
Closing price 04:00 PM Eastern
Extended Trading
$7.58 -0.09 (-1.11%)
As of 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Candel Therapeutics EPS Results

Actual EPS
-$0.74
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Candel Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Candel Therapeutics Announcement Details

Quarter
Q2 2024
Date
8/13/2024
Time
N/A
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Candel Therapeutics' Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, May 14, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Candel Therapeutics' Q2 2024 Press ReleasePress Release
(8-K)
Candel Therapeutics' Q2 2024 Quarterly reportQuarterly report
(10-Q)

Candel Therapeutics Earnings Headlines

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the ...
May 4 at 12:21 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/candel-therapeutics-to-host-investor-conference-call-following-presentation-of-extended-data-from-phase-3-trial-of-aglatimagene-besadenovec-in-localized-prostate-cancer-at-the-american-urological-1036100407
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
May 4 at 8:05 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3286676/0/en/candel-therapeutics-to-host-investor-conference-call-following-presentation-of-extended-data-from-phase-3-trial-of-aglatimagene-besadenovec-in-localized-prostate-cancer-at-the-amer.html
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
May 5 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/01/3286208/0/en/candel-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch
April 29, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1091417?snapi
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/29/3283732/0/en/candel-therapeutics-announces-commercialization-agreement-with-eversana-to-support-potential-u-s-launch-of-aglatimagene-besadenovec-in-localized-prostate-cancer.html
See More Candel Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Candel Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Candel Therapeutics and other key companies, straight to your email.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications. The company’s research and development activities are supported by a combination of in-house expertise in viral immunology and collaborations with academic institutions and contract research organizations. Preclinical studies have demonstrated the potential of Candel’s viral platforms to reshape the tumor microenvironment and synergize with checkpoint inhibitors and other immunotherapies.

Headquartered in Pittsburgh, Pennsylvania, Candel Therapeutics conducts clinical trials across multiple sites in North America and Europe. The company was founded by scientists with deep expertise in oncolytic virotherapy and has assembled a management team experienced in advancing viral therapies through regulatory interactions. As a public company listed on Nasdaq under the ticker CADL, Candel continues to expand its scientific capabilities and clinical footprint to bring innovative viral immunotherapies to patients worldwide.

View Candel Therapeutics Profile
Earnings Tools